New Data Highlight Value of Corus® CAD in Reducing Unnecessary Cardiac Testing and Costs for Women with Symptoms Suggestive of Obstructive Coronary Artery Disease
Corus® CAD Has Potential to Reduce Cardiac Diagnostic Costs in Women by More Than $500 per Patient
PALO ALTO, Calif., Oct. 10, 2013 /PRNewswire/ — CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced results of two studies indicating that Corus® CAD, a blood-based gene expression test, may help reduce unnecessary cardiac testing and costs by aiding clinician decision-making in the evaluation of women with symptoms suggestive of obstructive coronary artery disease (CAD). The studies were presented at The North American Menopause Society (NAMS) 2013 Annual Meeting, taking place October 9-12, 2013 in Dallas, TX.
© 2021 Pappas Capital, LLC. ALL RIGHTS RESERVED.